{
    "clinical_study": {
        "@rank": "112732", 
        "acronym": "RHT", 
        "arm_group": {
            "arm_group_label": "Treated Group", 
            "arm_group_type": "Experimental", 
            "description": "This group will receive actual shockwave treatment"
        }, 
        "brief_summary": {
            "textblock": "Low intensity shockwaves have been proven in animal and human studies to increase tissue\n      perfusion, promote angiogenesis and tissue regeneration and improve neural function.\n\n      The hypothesis of this study is that shockwave therapy could improve the symptoms of\n      patients with resistant hypertension."
        }, 
        "brief_title": "Safety and Efficacy Study of Extracorporeal Shockwave Therapy in the Treatment of Patients With Resistant Hypertension", 
        "condition": "Hypertension, Resistant to Conventional Therapy", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who have provided written informed consent.\n\n          -  Age \u226518 and \u226480 years old.\n\n          -  Office systolic blood pressure that remains \u2265160 mmHg (\u2265150 mmHg for patient with\n             type 2 diabetes) despite the stable use of \u22653 antihypertensive medications\n             concurrently at maximally tolerated doses, of which one is a diuretic (unless there\n             is a tolerance or a contraindication for a diuretics).\n\n          -  Able and willing to comply with the required follow-up schedule.\n\n        Exclusion Criteria:\n\n          -  Subjects who have participated in a clinical study involving another investigational\n             drug or device within 4 weeks prior to Screening.\n\n          -  Have hypertension secondary to an identifiable and treatable cause or take medication\n             that can raise the BP.\n\n          -  Prior renal artery intervention (balloon angioplasty or stenting).\n\n          -  Pregnancy.\n\n          -  Uncompensated heart failure.\n\n          -  Chronic Liver Disease.\n\n          -  Patients with skin wound / infection at the treatment area.\n\n          -  Subjects who take oral anti-coagulants.\n\n          -  Local tumor of treatment area."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02042066", 
            "org_study_id": "RHT-01", 
            "secondary_id": "0449-13"
        }, 
        "intervention": {
            "arm_group_label": "Treated Group", 
            "description": "Energy Density: 0.09 - 0.1 mJ/mm2 Extracorporeal Shockwave Therapy", 
            "intervention_name": "Omnispec model Vascuspec", 
            "intervention_type": "Device", 
            "other_name": "Vascuspec"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Resistant Hypertension", 
            "RH", 
            "RHT", 
            "Blood Pressure", 
            "Kidney", 
            "Shockwave"
        ], 
        "lastchanged_date": "January 21, 2014", 
        "location": {
            "contact": {
                "email": "aye.shauer@gmail.com", 
                "last_name": "Ayelet Shauer, MD", 
                "phone": "+972-2-6776564"
            }, 
            "facility": {
                "address": {
                    "city": "Jerusalem", 
                    "country": "Israel", 
                    "zip": "91120"
                }, 
                "name": "Hadassah Medical Organization"
            }, 
            "investigator": [
                {
                    "last_name": "Ayelet Shauer, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "David Libovitz, Professor", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ido Ben-Dov, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Shmuel Hen, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Amir Orlev, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "Efficacy and Safety of Low Intensity- Extracorporeal Shockwave Therapy in Drug Resistant Hypertension", 
        "overall_contact": {
            "email": "aye.shauer@gmail.com", 
            "last_name": "Ayelet Shauer, MD", 
            "phone": "+972-2-6776564"
        }, 
        "overall_official": {
            "affiliation": "Hadassah Medical Organization", 
            "last_name": "Ayelet Shauer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Change in 24 hour ambulatory blood pressure (ABPM) from baseline to six months post last treatment (\u00b1 2 weeks)", 
                "measure": "Ambulatory Blood Pressure Monitoring (ABPM)", 
                "safety_issue": "No", 
                "time_frame": "6 Months"
            }, 
            {
                "description": "Change in 24 hour ambulatory blood pressure (ABPM) from baseline to three months post last treatment (\u00b1 2 weeks)", 
                "measure": "Ambulatory Blood Pressure Monitoring (ABPM)", 
                "safety_issue": "No", 
                "time_frame": "3 Months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02042066"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in office blood pressure from baseline to three months and six months post last treatment (\u00b1 2 weeks).", 
                "measure": "Office Blood Pressure", 
                "safety_issue": "No", 
                "time_frame": "6 Months"
            }, 
            {
                "description": "Change in serum  urea and creatinine from baseline to 3 months and 6 months (\u00b1 2 weeks) post last treatment", 
                "measure": "Serum Urea and Creatinine", 
                "safety_issue": "No", 
                "time_frame": "3 Months"
            }, 
            {
                "description": "Change in ultrasound-measured renal resistive index (RRI)", 
                "measure": "Ultrasound", 
                "safety_issue": "No", 
                "time_frame": "3 Months"
            }, 
            {
                "description": "Change in serum  urea and creatinine from baseline to 3 months and 6 months (\u00b1 2 weeks) post last treatment", 
                "measure": "Serum Urea and Creatinine", 
                "safety_issue": "No", 
                "time_frame": "6 Months"
            }, 
            {
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "6 Months"
            }, 
            {
                "description": "Change in office blood pressure from baseline to three months and six months post last treatment (\u00b1 2 weeks).", 
                "measure": "Office Blood Pressure", 
                "safety_issue": "No", 
                "time_frame": "3 Months"
            }
        ], 
        "source": "Medispec", 
        "sponsors": {
            "collaborator": {
                "agency": "Hadassah Medical Organization", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Medispec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2015", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}